Microgen's preparation for chronic migraines has been approved by the Ministry of Health in Kyrgyzstan

SPA Microgen (part of Nacimbio Holding of Rostec State Corporation) has received the approval of the Ministry of Health of Kyrgyzstan for the application of the RELATOX drug in the territory of the Republic for two new indications – treatment of chronic migraine and correction of neck wrinkles.

SPA Microgen is one of the leading Russian manufactures of botulinum toxin type A with a market share of 35% (based on 2023 results). RELATOX is a myorelaxant of peripheral action, which has been successfully used in Russia for more than 10 years in cosmetology and neurology. Its action is aimed at reducing muscle hypertonus by blocking transmission in the neuromuscular junction.

Registration of two new indications of the drug in Kyrgyzstan was based on data from clinical trials implemented in Russia. In 2022, SPA Microgen successfully completed the RELATOX study to evaluate efficacy and safety in chronic migraine therapy in a group of patients 18 to 65 years of age. According to the results obtained, the drug has a positive effect on the quantitative characteristics of the disease, as well as on the quality of life of patients with chronic migraine. The volunteers have decreased the time spent on headache treatment by 9 days per month, as well as the symptoms of migraines, such as nausea, photophobia, and phonophobia.

Chronic migraine is currently the leading neurological disorder and one of the most common causes of declining quality of life worldwide. Despite this, epidemiological data on this disease is often poorly documented and undiagnosed. Within a year, headaches affect anywhere from 50 to 70% of adults between 18 and 65, with migraines being the most common cause. Only a small percentage of individuals suffering from headaches seek professional help for diagnosis and treatment.

Inclusion of such indication as correction of vertical neck wrinkles in the RELATOX instructions for use was based on the results of a randomized multicenter study, implemented on the basis of four research centers in Moscow, Nizhny Novgorod, Krasnoyarsk and St. Petersburg from June 2020 to December 2022. The findings confirmed that the use of the drug significantly reduces the severity of platysmal bands – vertical neck wrinkles, which appear because of the hypertone of the flat surface muscle stretching from the breast line to the mandible.


“We highly appreciate the trade and economic relations established between our company and Kyrgyzstan. It is the first country among other states to approve RELATOX for such indications as chronic migraine and correction of vertical neck wrinkles on its territory. We have no doubt that RELATOX will enjoy the same trust of patients and doctors in Kyrgyzstan as in Russia – told in Microgen”.

RELATOX is intended for the treatment of facial and neck wrinkles, as well as for the treatment of a number of neurological diseases, including blepharospasm, cervical dystonia (spastic torticollis), axillary hyperhidrosis, chronic migraine in adults, upper and lower extremities muscle spasticity in children 2-17 years of age with infantile cerebral paralysis and focal spasticity of upper extremity muscles in adults. The drug won many rewards in Russia, including the All-Russian prize in the field of import substitution «Project leader» and the national prize «Priority».

RELATOX is produced at SPA «Microgen» in Ufa through a full-cycle technology. Since 2014, the drug is available to patients in all regions of Russia, as well as in Belarus, Uzbekistan and Kyrgyzstan.